These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 29424288)

  • 41. ▼Relvar Ellipta for COPD.
    Drug Ther Bull; 2014 Jun; 52(6):66-9. PubMed ID: 24904005
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Fluticasone furoate and vilanterol inhalation powder for the treatment of chronic obstructive pulmonary disease.
    Matera MG; Capuano A; Cazzola M
    Expert Rev Respir Med; 2015 Feb; 9(1):5-12. PubMed ID: 25482512
    [TBL] [Abstract][Full Text] [Related]  

  • 43. In vitro dose comparison of Respimat
    Ciciliani AM; Langguth P; Wachtel H
    Int J Chron Obstruct Pulmon Dis; 2017; 12():1565-1577. PubMed ID: 28603412
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Patient perception of Breezhaler
    Altman P; Bergna MA; Garcia GR; Guerin T; Pino AV; Whiteford JL
    Curr Med Res Opin; 2019 Feb; 35(2):221-227. PubMed ID: 29649916
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Inhalation characteristics of asthma patients, COPD patients and healthy volunteers with the Spiromax® and Turbuhaler® devices: a randomised, cross-over study.
    Azouz W; Chetcuti P; Hosker H; Saralaya D; Chrystyn H
    BMC Pulm Med; 2015 May; 15():47. PubMed ID: 25927483
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The importance of inhaler devices: the choice of inhaler device may lead to suboptimal adherence in COPD patients.
    Darbà J; Ramírez G; Sicras A; Francoli P; Torvinen S; Sánchez-de la Rosa R
    Int J Chron Obstruct Pulmon Dis; 2015; 10():2335-45. PubMed ID: 26604733
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Inhalatory therapy training: a priority challenge for the physician.
    Melani AS
    Acta Biomed; 2007 Dec; 78(3):233-45. PubMed ID: 18330086
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Factors associated with appropriate inhaler use in patients with COPD - lessons from the REAL survey.
    Price D; Keininger DL; Viswanad B; Gasser M; Walda S; Gutzwiller FS
    Int J Chron Obstruct Pulmon Dis; 2018; 13():695-702. PubMed ID: 29520137
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Relvar Ellipta for asthma.
    Drug Ther Bull; 2014 Aug; 52(8):93-6. PubMed ID: 25125553
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Assessment of inhalation flow patterns of soft mist inhaler co-prescribed with dry powder inhaler using inspiratory flow meter for multi inhalation devices.
    Hira D; Koide H; Nakamura S; Okada T; Ishizeki K; Yamaguchi M; Koshiyama S; Oguma T; Ito K; Funayama S; Komase Y; Morita SY; Nishiguchi K; Nakano Y; Terada T
    PLoS One; 2018; 13(2):e0193082. PubMed ID: 29462195
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evaluation of dry powder inhalers with a focus on ease of use and user preference in inhaler-naïve individuals.
    von Schantz S; Katajavuori N; Antikainen O; Juppo A
    Int J Pharm; 2016 Jul; 509(1-2):50-58. PubMed ID: 27208655
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Inhaler technique and patient's preference for dry powder inhaler devices.
    Lavorini F; Fontana GA
    Expert Opin Drug Deliv; 2014 Jan; 11(1):1-3. PubMed ID: 24093806
    [TBL] [Abstract][Full Text] [Related]  

  • 53. New treatments for chronic obstructive pulmonary disease and viable formulation/device options for inhalation therapy.
    Onoue S; Misaka S; Kawabata Y; Yamada S
    Expert Opin Drug Deliv; 2009 Aug; 6(8):793-811. PubMed ID: 19558334
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Optimising Inhaled Pharmacotherapy for Elderly Patients with Chronic Obstructive Pulmonary Disease: The Importance of Delivery Devices.
    Lavorini F; Mannini C; Chellini E; Fontana GA
    Drugs Aging; 2016 Jul; 33(7):461-73. PubMed ID: 27216613
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Persistence to treatment by type of inhaler device in patients with asthma and chronic obstructive pulmonary disease].
    Sicras A; Ferrer V; Collar JM; Navarro R; Sáez M
    Semergen; 2017; 43(5):375-386. PubMed ID: 27425817
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A Randomized Clinical Trial Comparing the ELLIPTA and HandiHaler Dry Powder Inhalers in Patients With COPD: Inhaler-Specific Attributes and Overall Patient Preference.
    Collison KA; Patel P; Preece AF; Stanford RH; Sharma RK; Feldman G
    COPD; 2018 Feb; 15(1):46-50. PubMed ID: 29227727
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [The choice of inhalation device: A medical act].
    Devillier P; Salvator H; Roche N
    Rev Mal Respir; 2015 Jun; 32(6):599-607. PubMed ID: 25433462
    [TBL] [Abstract][Full Text] [Related]  

  • 58. In Vitro Comparison of Two Blister-Type Inhalers.
    Kondo T; Tanigaki T; Hibino M; Tajiri S; Horiuchi S; Maeda K; Tobe S
    Respir Care; 2023 Mar; 68(3):338-345. PubMed ID: 36100278
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Understanding Dry Powder Inhalers: Key Technical and Patient Preference Attributes.
    Levy ML; Carroll W; Izquierdo Alonso JL; Keller C; Lavorini F; Lehtimäki L
    Adv Ther; 2019 Oct; 36(10):2547-2557. PubMed ID: 31478131
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Use and inhalation technique of inhaled medication in patients with asthma and COPD: data from a randomized controlled trial.
    Gregoriano C; Dieterle T; Breitenstein AL; Dürr S; Baum A; Maier S; Arnet I; Hersberger KE; Leuppi JD
    Respir Res; 2018 Dec; 19(1):237. PubMed ID: 30509268
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.